159 related articles for article (PubMed ID: 21919605)
1. The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
Afzal S; Gusella M; Jensen SA; Vainer B; Vogel U; Andersen JT; Brødbæk K; Petersen M; Jimenez-Solem E; Adleff V; Budai B; Hitre E; Láng I; Orosz E; Bertolaso L; Barile C; Padrini R; Kralovánszky J; Pasini F; Poulsen HE
Pharmacogenomics; 2011 Sep; 12(9):1257-67. PubMed ID: 21919605
[TBL] [Abstract][Full Text] [Related]
2. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
[TBL] [Abstract][Full Text] [Related]
3. Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
Sarac SB; Rasmussen CH; Afzal S; Thirstrup S; Jensen SA; Colding-Jørgensen M; Poulsen HE; Mosekilde E
Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):189-97. PubMed ID: 22448752
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
6. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
[TBL] [Abstract][Full Text] [Related]
8. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
Rumiato E; Boldrin E; Amadori A; Saggioro D
Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
11. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
12. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
[TBL] [Abstract][Full Text] [Related]
13. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
[TBL] [Abstract][Full Text] [Related]
14. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
Park CM; Lee WY; Chun HK; Cho YB; Yun HR; Heo JS; Yun SH; Kim HC
J Surg Oncol; 2010 Jan; 101(1):22-7. PubMed ID: 19798689
[TBL] [Abstract][Full Text] [Related]
15. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
Ichikawa W; Takahashi T; Suto K; Sasaki Y; Hirayama R
Clin Cancer Res; 2006 Jul; 12(13):3928-34. PubMed ID: 16818689
[TBL] [Abstract][Full Text] [Related]
16. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
18. Investigation of
Cevik M; Namal E; Sener ND; Koksal UI; Cagatay P; Deliorman G; Ciftci C; Karaalp A; Susleyici B
Per Med; 2022 Sep; 19(5):435-444. PubMed ID: 35880438
[TBL] [Abstract][Full Text] [Related]
19. Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
Goto T; Shinmura K; Yokomizo K; Sakuraba K; Kitamura Y; Shirahata A; Saito M; Kigawa G; Nemoto H; Sanada Y; Hibi K
Anticancer Res; 2012 May; 32(5):1757-62. PubMed ID: 22593457
[TBL] [Abstract][Full Text] [Related]
20. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]